UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

The New England journal of medicine, 2021-05, Vol.384 (20), p.1885-1898

2021

Link zum Volltext

Verfügbarkeit prüfen

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Nature (London), 2021-04, Vol.592 (7853), p.283

2021

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact

Nature reviews. Immunology, 2022-01, Vol.22 (1), p.57

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

The New England journal of medicine, 2020-12, Vol.383 (27), p.2603-2615

2020

Link zum Volltext

Verfügbarkeit prüfen

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

The Lancet (British edition), 2021-05, Vol.397 (10289), p.2043-2046

2021

Link zum Volltext

Verfügbarkeit prüfen

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

The New England journal of medicine, 2021-05, Vol.384 (19), p.1824-1835

2021

Link zum Volltext

Verfügbarkeit prüfen

Model-informed COVID-19 vaccine prioritization strategies by age and serostatus

Science (American Association for the Advancement of Science), 2021-02, Vol.371 (6532), p.916-921

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

The New England journal of medicine, 2021-09, Vol.385 (13), p.1172-1183

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

The Lancet infectious diseases, 2021-02, Vol.21 (2), p.181-192

2021

Link zum Volltext

Verfügbarkeit prüfen

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Nature reviews. Immunology, 2021-10, Vol.21 (10), p.626

2021

Link zum Volltext

Verfügbarkeit prüfen

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

JAMA : the journal of the American Medical Association, 2022-02, Vol.327 (7), p.639

2022

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron

Cell, 2022-03, Vol.185 (5), p.847-859.e11

2022

Link zum Volltext

Verfügbarkeit prüfen

Considerations in boosting COVID-19 vaccine immune responses

The Lancet (British edition), 2021-10, Vol.398 (10308), p.1377-1380

2021

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 vaccines: The status and perspectives in delivery points of view

Advanced drug delivery reviews, 2021-03, Vol.170, p.1-25

2021

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Nature communications, 2021-01, Vol.12 (1), p.372-372, Article 372

2021

Link zum Volltext

Verfügbarkeit prüfen

Seroconversion rates following COVID-19 vaccination among patients with cancer

Cancer cell, 2021-08, Vol.39 (8), p.1081-1090.e2

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

The Lancet infectious diseases, 2021-12, Vol.21 (12), p.1645-1653

2021

Link zum Volltext

Verfügbarkeit prüfen

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Nature reviews. Immunology, 2021-08, Vol.21 (8), p.475

2021

Link zum Volltext

Verfügbarkeit prüfen

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Nature (London), 2022-02, Vol.602 (7898), p.676

2022

Link zum Volltext

Verfügbarkeit prüfen

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

The Lancet (British edition), 2022-01, Vol.399 (10321), p.237-248

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

The Lancet (British edition), 2021-09, Vol.398 (10303), p.856-869

2021

Link zum Volltext

Verfügbarkeit prüfen

Diagnostics for COVID-19: moving from pandemic response to control

The Lancet (British edition), 2022-02, Vol.399 (10326), p.757-768

2022

Link zum Volltext

Verfügbarkeit prüfen

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

Nature (London), 2022-01, Vol.601 (7894), p.617

2022

Link zum Volltext

Verfügbarkeit prüfen

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study

BMJ (Online), 2021-08, Vol.374, p.n1931

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.352

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.214)
Mit Volltextzugriff
(1.915)

Publikationsform

Artikel
(2.343)
magazinearticle
(9)

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.115)
Humans
(2.096)
Life Sciences & Biomedicine
(1.875)
Covid-19
(1.518)
Covid-19 - Prevention & Control
(1.407)
Covid-19 Vaccines - Administration & Dosage
(1.404)
Covid-19 Vaccines
(1.182)
Vaccines
(1.150)
Coronaviruses
(1.116)
Severe Acute Respiratory Syndrome Coronavirus 2
(891)
Sars-Cov-2
(890)
Vaccination
(872)
Pandemics
(764)
Female
(745)
Immunization
(698)
Male
(651)
Covid-19 - Epidemiology
(629)
Adult
(581)
Sars-Cov-2 - Immunology
(553)
Public Health
(533)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Mmwr. Morbidity And Mortality Weekly Report
(86)
Morbidity And Mortality Weekly Report
(81)
Nature
(78)
Vaccines
(73)
Plos One
(71)
The Lancet
(60)
Vaccine
(59)
Viruses
(58)
The New England Journal Of Medicine
(51)
Jama : The Journal Of The American Medical Association
(46)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Model-informed COVID-19 vaccine prioritization strategies by age and serostatus

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron

Considerations in boosting COVID-19 vaccine immune responses

COVID-19 vaccines: The status and perspectives in delivery points of view

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Seroconversion rates following COVID-19 vaccination among patients with cancer

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Diagnostics for COVID-19: moving from pandemic response to control

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study

Suchergebnisse filtern